Author:
Matrevi Sena Adzoa,Tandoh Kwesi Zandoh,Bruku Selassie,Opoku-Agyeman Philip,Adams Tryphena,Ennuson Nana Aba,Asare Bright,Hagan Oheneba Charles Kofi,Abuaku Benjamin,Koram Kwadwo Ansah,Fox Ann,Quashie Neils Ben,Letizia Andrew G.,Duah-Quashie Nancy Odurowah
Abstract
AbstractThe molecular determinants of Plasmodium falciparum artemisinin resistance are the single nucleotide polymorphisms in the parasite’s kelch propeller domain, pfk13. Validated and candidate markers are under surveillance in malaria endemic countries using artemisinin-based combination therapy. However, pfk13 mutations which may confer parasite artemisinin resistance in Africa remains elusive. It has therefore become imperative to report all observed pfk13 gene polymorphisms in malaria therapeutic efficacy studies for functional characterization. We herein report all novel pfk13 mutations observed only in the Ghanaian parasite population. In all, 977 archived samples from children aged 12 years and below with uncomplicated malaria from 2007 to 2017 were used. PCR/Sanger sequencing analysis revealed 78% (763/977) of the samples analyzed were wild type (WT) for pfk13 gene. Of the 214 (22%) mutants, 78 were novel mutations observed only in Ghana. The novel SNPs include R404G, P413H, N458D/H/I, C473W/S, R529I, M579T/Y, C580R/V, D584L, N585H/I, Q661G/L. Some of the mutations were sites and ecological zones specific. There was low nucleotide diversity and purifying selection at the pfk13 locus in Ghanaian parasite population. With increasing drug pressure and its consequent parasite resistance, documenting these mutations as baseline data is crucial for future molecular surveillance of P. falciparum resistance to artemisinin in Ghana.
Funder
Global Emerging Infections Surveillance and Response Section (GEIS), a division of the US Armed Forces Health Surveillance Center
Global Fund to fight Aids, Tuberculosis and Malaria (GFATM)/National Malaria Control Programme
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. WHO. World Malaria Report 2020 (World Health Organization, Geneva, 2020).
2. WHO. Antimalarial Drug Combination Therapy Report of a WHO Technical Consultation (World Health Organization, Geneva, 2001).
3. Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411–423. https://doi.org/10.1056/NEJMoa1314981 (2014).
4. Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50–55. https://doi.org/10.1038/nature12876 (2014).
5. WHO. Artemisinin Resistance and Artemisinin-Based Combination Therapy Efficacy (World Health Organization, Geneva, 2018).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献